Man is the new mouse: Elective surgery as a key translational model for multi-organ dysfunction and sepsis

Abstract

Translational research in critically ill human patients presents many methodological challenges. Diagnostic uncertainty, coupled with poorly defined comorbidities, make the identification of a suitable control population for case–control investigations an arguably insurmountable challenge. Healthy volunteer experiments using endotoxin infusion as an inflammatory model are methodologically robust, but fail to replicate the onset of, and diverse therapeutic interventions associated with, sepsis/trauma. Animal models are also limited by many of these issues. Major elective surgery addresses many of these shortfalls and offers a key model for exploring the human biology underlying the sepsis syndrome. Surgery triggers highly conserved features of the human inflammatory response that are common to both tissue damage and infection. Surgical patients sustain a predictable and relatively high incidence of sepsis, particularly within the ‘higher risk’ group. The collection of preoperative samples enables each patient to act as their own control. Thus, the surgical model offers unique and elegant experimental design features that provide an important translational bridge between the basic biological understanding afforded by animal laboratory models and the de novo presentation of human sepsis.

Keywords

Surgery animal model sepsis research human

Introduction

In comparison to major acute medical pathologies, the comparative dearth of novel therapeutic agents, persistently high morbidity and significant mortality that characterise sepsis syndrome is striking.^1–5 A lack of suitable human models that afford a methodologically robust control population for mechanistic studies may explain this lack of progress. Mechanistic research in patients with established sepsis has failed to overcome several key methodological limitations. Eliminating confounding factors from case–control study design in established sepsis is challenging, if not impossible. Age,⁶ gender,^7,8 ethnicity⁹ and comorbidity^10,11 all profoundly alter normal physiological function. Therapeutic agents commonly used to treat sepsis, including antibiotics,^12,13 sedatives¹⁴ and steroids,¹⁵ all exert off-target immunologic and metabolic effects. These factors alter multi-organ function and therefore confound the biological and clinical interpretation of experimental readouts being attributed to sepsis syndrome per se. However, the default control population for critical illness studies using case–control methodology has typically been healthy volunteers. By contrast, elucidating mechanisms through cohort studies where a population is followed until a disease occurs is clearly more methodologically robust, because samples are taken from study participants prior to the onset of organ dysfunction. In order to be economically viable and relevant research, the cohort must have a predictably high incidence of sepsis and be comparable to the septic population of interest. This article sets out the case for major surgery fulfilling these criteria, and highlights recent data demonstrating the superior suitability of this model being adopted.

Diagnostic uncertainty confounds the study of sepsis syndrome

Clinical suspicion of infection, rather than objective microbiological evidence, is advocated by the Surviving Sepsis Campaign guidelines,¹⁶ as well as the majority of large scale clinical trials conducted recently (Table 1). While this pragmatic approach is currently required to guide immediate bedside therapy, it is surprising that the independent/objective confirmation of sepsis is frequently scarce. Even translational studies, where the number of subjects is much smaller than larger clinical trials, seldom provide this information.¹⁷ New technologies – such as digital PCR – may improve bedside diagnostic certainty and precision.¹⁸ Individual pathogens contribute important additional complexity, since interactions and cellular signalling are in part determined by different pathogenic organisms.^19,20 The indeterminate onset and variable clinical phenotype of sepsis makes the accurate time-stamping of patient samples and administration of therapies difficult to define. Such timing is critical if dynamic biological processes are only amenable to successful intervention during critical time windows, for which there is solid experimental evidence.²¹ Thus, several clinical factors distort the ‘signal-to-noise’ ratio significantly.

Table 1.

The definitions of sepsis and criteria for diagnosis of infection used by major clinical trials published between October 2013 and October 2014.

Author (year)	Journal	Data collection	Clinical inclusion criteria	Infection criteria	Consensus committee review of micro-biology	Sepsis definition reference
Raghunathan et al. (2014) ¹⁰³	Critical Care Medicine	Retrospective	ICD-8-CM coding + on icu + receiving vasopressor	Antibiotic administration for 3 days/blood cultures	No	Not specified
ProCESS Investigators et al. (2014) ¹⁰⁴	NEJM	Prospective	Septic shock	Clinically suspected infection	No	ACCP/SCCM Bone (1992)¹⁰⁵
Caironi et al. (2014) ¹⁰⁶	NEJM	Prospective	Severe sepsis	Clinically suspected infection	No	ACCP/SCCM Bone (1992)¹⁰⁵
Asfar et al. (2014) ¹⁰⁷	NEJM	Prospective	Septic shock	Clinically suspected infection	No	ACCP/SCCM Bone (1992)¹⁰⁵
Gordon et al. (2014) ¹⁰⁸	Critical Care Medicine	Prospective	Septic shock	Clinically suspected infection	No	ACCP/SCCM Bone (1992)¹⁰⁵
Bernard et al. (2014) ¹⁰⁹	Critical Care Medicine	Prospective	Severe sepsis/septic shock	Clinically suspected infection (criteria specified)	No	Not specified
Morelli et al. (2013) ¹¹⁰	JAMA	Prospective	Septic shock	Not specified	No	Not specified

A Pubmed search was performed using the following criteria: ‘Sepsis’ [MeSH Major Topic] + ‘Clinical Trial’ [MeSH term] + ‘Human’ [MeSH term]. NEJM: New England Journal of Medicine; JAMA: Journal of the American Medical Association; ACCP/SCCM: American College of Chest Physicians and Society of Critical Care Medicine.

Animal models fail to recapitulate the clinical phenotype of human sepsis

Fundamental biological processes and signalling pathways are highly conserved across species. The unprecedented opportunity to develop organ-specific transgenic models has provided essential insights into physiological and pathophysiological mechanisms. For example, murine models of cardiac injury are highly tractable in relation to translational human work. By contrast, murine/rodent models of sepsis have garnered much criticism. In part, the combination of costly alternatives, prohibitive legislation and seductive impact of transgenic murine technology have driven sepsis research into utilising mouse models. However, the genomic responses of mouse models poorly mimic human inflammatory disease. In humans, highly conserved mRNA expression is observed in circulating leukocytes following traumatic injury, burns and endotoxin infusion.^22,23 By contrast, these genomic changes do not correlate with murine homologs, which in turn demonstrate much greater variation in response to disparate inflammatory stimuli.²² Of course, this may merely reflect the impact of clinical interventions that influence morbidity and mortality in human sepsis (e.g. fluid resuscitation), many of which are not taken into account or are technically challenging in murine research models exploring trauma/sepsis. Nevertheless, even allowing for genetic variability amongst murine strains which influence survival,^24,25 other major physiologic differences in metabolism,²⁶ cardiovascular control²⁷ and gut flora²⁸ suggest that cautious extrapolation is clearly warranted. However, the detection of tissue injury through Pattern recognition receptors (PRR)^29,30 and antimicrobial arsenal³¹ also differ between the two species. Up to 10,000-fold higher doses of lipopolysaccharide are required in rodents to create a clinically significant sepsis syndrome.³² The distribution of leukocyte subsets across sites of infection, including the lungs and gastrointestinal tract, differs substantially.^29,33 Humanised immunologic murine models, where human haematopoietic cells and tissues are engrafted into immunodeficient mice, may help circumnavigate some of these challenges.^34,35 Death in septic laboratory models is relatively rapid and frequently occurs as a direct consequence of early pathologic changes.³² By contrast, in humans death from sepsis is usually from delayed multi-organ dysfunction following resuscitation and therapeutic support, rather than a rapid demise from the initial pathogenic trigger.³⁶ Arguably, many of the clinical features of human sepsis syndrome are difficult to disentangle from the consequences of iatrogenic intervention,^37,38 which are delivered on basis of illness severity. While animal models remain essential for molecular pathway characterisation and early drug testing, there is a clear need for additional translational models that facilitate the study of human sepsis with superior fidelity.

Administration of endotoxin to healthy volunteers partially mimics sepsis syndrome

The infusion of endotoxin and specific cytokines generates a short-term model that mimics aspects of the systemic inflammatory response.³⁹ However, for clear ethical reasons, the doses administered cannot either replicate, or trigger the sequelae leading to, end-organ dysfunction following severe sepsis. Dynamic changes in cytokine expression – a commonly used descriptor of inflammation – following the administration of endotoxin⁴⁰ differ markedly from the patterns observed in patients with established sepsis.⁴¹ Furthermore, comorbidities,^10,11 medication^12,14,15 and clinical interventions^42,43 are important features of patients that impact on these signatures of inflammation.⁴⁴

Sepsis following elective surgery is sufficiently common to make cohort studies of clinical sepsis feasible

Approximately 234 million surgical procedures are performed worldwide each year,⁴⁵ and sepsis syndrome is under-appreciated (yet frequently observed) within selected high-risk surgical groups.⁴⁶ Even in prospective randomised controlled trials that aim to reduce surgical site infections, the incidence in either trial arm frequently exceeds 15%.^47,48,49 Comorbidities associated with the greatest risk of postoperative complications and sepsis syndrome, include immunosuppressive disease,⁵⁰ malnutrition,^51,52 advanced age^50,53–55 cancer^50,53,56 and congestive cardiac failure,^50,56,57 all of which are similarly over-represented in the non-surgical population who acquire sepsis syndrome.⁵⁸

Major elective surgery is undertaken in a highly phenotyped population

Major elective surgery provides a model whereby a known reproducible inflammatory insult may be administered at a specific time to a patient that acts as their own control. The magnitude of the surgical insult can be predicted and/or relatively controlled by standardised surgical and peri-operative interventions. Protocolised clinical management may minimise variability.⁵⁹ Patients undergoing major surgery can undergo extensive pre-operative phenotyping, enabled by the full range of ‘omic’ technology, including characterisation of baseline organ function (imaging, biochemistry, exercise capacity) and the detection of overt or occult pathophysiology.⁶⁰ Since the volume of surgery is huge (estimated at >234 million procedures/year worldwide),⁴⁵ large numbers of patients may be recruited.

Timing is everything: Serial accessibility of tissue and physiologic data

With carefully considered experimental design, many surgical procedures permit the concurrent acquisition of tissue and physiologic data. Beyond the potentially highly phenotyped standardised pre-operative workup, the serial sampling of tissue (including blood,⁶¹ muscle,⁶² wound^63,64 and indwelling catheters⁶⁵) coupled with advanced non-invasive imaging modalities^66,67 afford increasingly sophisticated readouts referenced to an individual’s own control data.

Surgery as the definitive human model of damage-associated molecular patterns-induced sepsis syndrome

Surgical or traumatic tissue injury causes a systemic inflammatory syndrome that clinically mimics sepsis syndrome. Damage-associated molecular patterns (DAMPs) released following cellular injury activate innate and adaptive immunocytes through PRRs, in a manner broadly similar to pathogen-associated molecular patterns (PAMPs) (Figure 1). Circulating levels of mitochondrial DNA are a thousand-fold higher in major trauma patients compared to healthy volunteers,⁶⁸ and post-injury plasma levels are associated with mortality.⁶⁹ Infusion of mitochondrial formyl peptides into rats recreates a sepsis syndrome phenotype characterised by neutrophil, albumin and fluid accumulation within the lungs. Co-administration of formyl peptide blocking antibodies limits this injury. The observation that both DAMPs and PAMPs trigger a similar clinical appearance is biologically predictable, since tissue trauma releases these mitochondrial-derived DAMPs that share evolutionarily conserved signalling properties with bacterial PAMPs.^70,71 The interaction between conserved, shared signalling mechanisms used by DAMPs and PAMPs is likely to be critical for understanding both the development and response to sepsis syndrome.

Figure 1.

Critical shared steps during the inflammatory response to infection and tissue injury. Infection causes local tissue injury and tissue injury predisposes to infection – both stimuli lead to release of Damage Associated Molecular Patterns (DAMPs) and Pathogen Associated Molecular Patterns (PAMPs). DAMPs and PAMPs are recognised by the same Pattern Recognition Receptors, including Toll-Like Receptors (TLRs), Nod-Like Receptors (NLRs) and Rig-Like Receptors (RIGs). Activation of these receptors leads to NK-kB expression and formation of a range of inflammasomes. Inflammasomes are large subunit oligomers that represent an all-or-nothing step in the summation of a cells response to inflammatory stimuli. They are platforms where pivotal pro-inflammatory compounds such as IL-1β are synthesised. Adapted from Mollen et al.¹¹¹

Examples of peri-operative biology preceding pivotal advances in critical illness

Mechanical ventilation is a common mode of injury in both critically ill and surgical patients, which may be, in part, determined by DAMP release. While lung protective ventilation has an established role in the management of Acute Respiratory Distress Syndrome (ARDS)⁴² randomised controlled trials of this strategy in elective surgical patients provided some of the first and most robust human data that specific ventilation practices alone directly cause alveolar injury.⁷² Elsewhere one lung ventilation during elective surgery has been used as a model of human acute lung injury for characterising the anti-inflammatory properties of beta agonists and 3-hydroxy-3-methyl-glutaryl-CoA (HMG CoA) reductase inhibitors.^73,74 prior to investigation of the same agents in those with established critical illness.⁷⁵ Key contributions from peri-operative biology to our understanding of sepsis syndrome are detailed in Figure 2.

Figure 2.

Mechanisms of sepsis syndrome uncovered by studying the biology of elective surgery.

Priming of organ injury is a ubiquitous feature of major surgery

Priming describes how the serial application of otherwise innocuous insults leads to far greater inflammatory response than would be expected from the summation of the two insults. In murine experimental models, ischaemic-reperfusion injury to the gut, followed by endotoxin, dramatically increases mortality when compared to either insult alone.⁷⁶ At a cellular level, priming may be partly explained by changes to neutrophil functionality and endothelial activation.⁷⁷ The same processes may explain the high incidence of ARDS and multi-organ failure that occur in trauma patients who suffer early complications.⁷⁸ It follows that major surgery may therefore prime patients for exaggerated responses to early postoperative complications. Interactions through Toll-Like Receptor 4 (TLR4), and associated pattern recognition receptors, provide a molecular explanation for the priming phenomenon. In murine models, functional TLR4 has been shown to be critical for the development of lung injury following haemorrhagic shock.^79,80 Beyond epithelial/immune cell interactions haemorrhagic shock has also been associated with activation of the NLRP3 inflammasome within lung endothelial cells.⁸¹ Thus, surgical tissue trauma priming provides an opportunity to investigate how subsequent cellular responses to endogenous (e.g. gut derived bacterial endotoxin)⁸² or acquired PAMPs alter subsequent cellular responses to further DAMP and/or PAMP encounters.

Cell-mediated immunosuppression following sepsis and surgery

The immunosuppressive phase of sepsis that follows the primary trigger is characterised by reactivation of latent viruses^83,84 and a failure to eradicate opportunistic and/or endogenous (gut) pathogens.⁸⁵ Experimental and clinical data show that apoptotic depletion of lymphocytes⁸⁶ increased T regulatory⁸⁷ and myeloid-derived suppressor cells⁸⁸ contributes to sepsis-induced immunosuppression. In surgical patients, pre-operative lymphopenia^89–92 and the failure to demonstrate a delayed-hypersensitivity response to intradermal injections of recall antigens (anergy)⁹³ are associated with an increased risk of developing sepsis syndrome postoperatively. Thus, striking similarities exist between the hyporesponsive phase following the onset of sepsis and the immunosuppression observed postoperatively.

A common mechanistic role for endotoxin?

Estimates of human bacterial floral content place the endogenous endotoxin reservoir within the order of grams,⁹⁴ many-fold more than the nanogram doses required to initiate a systemic inflammatory response.⁹⁵ Hypo-perfusion leading to translocation of gut derived endotoxin⁹⁶ may provide a common mechanism that drives the inflammatory response to diverse intestinal pathogens expressing virulence determinants triggered by environmental signals indicating host stress⁹⁷ (Figure 1). Endotoxaemia is detectable in patients who have severe sepsis regardless of causative organism,^98,99 and in those undergoing major surgery, such as vascular repair.⁹⁹ Within general intensive care patients endotoxaemia is associated with the severity of sepsis syndrome.⁹⁸ Pre-operative deficiency in antibodies to endotoxin is associated with higher levels of postoperative inflammation and excess morbidity.^100–102

Conclusion

Fundamental limitations in both animal and patient models have contributed to a lack of therapeutic progress in human sepsis. Surgery provides a biologically and clinically relevant model that avoids many such limitations. This human model enables the investigation of a timed, major inflammatory insult in highly phenotyped patients serving as their own control. Beyond the biological modelling of sepsis on the initial surgical insult, sepsis syndrome is sufficiently common and predictable within the large numbers of patients undergoing surgical procedures to enable cohort studies of sepsis itself. This clinical population offers an unparalleled opportunity to combine carefully planned mechanistic work as part of clinically relevant outcome, a feature frequently absent in critical care trials.

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

Marco Ranieri

Thompson

Philip

Barie . Drotrecogin Alfa (Activated) in adults with septic shock. N Engl J Med 2012; 366: 2055–2064.

Sprung

Annane

Keh

. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111–124.

Alejandria

Lansang

Dans

. 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013; 9: CD001090.

Angus

Birmingham

Balk

. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. JAMA 2000; 283: 1723–1730.

Rimmer

Kumar

Doucette

. Activated protein C and septic shock: a propensity-matched cohort study. Crit Care Med 2012; 40: 2974–2981.

Montecino-Rodriguez

Berent-Maoz

Dorshkind

. Causes, consequences, and reversal of immune system aging. J Clin Invest 2013; 123: 958–965.

Frink

Pape

van Griensven

. Influence of sex and age on mods and cytokines after multiple injuries. Shock 2007; 27: 151–156.

Sakr

Elia

Mascia

. The influence of gender on the epidemiology of and outcome from severe sepsis. Crit Care 2013; 17: R50.

Mayr

Yende

Linde-Zwirble

. Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis. JAMA 2010; 303: 2495–2503.

10.

Fildes

Shaw

Yonan

. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol 2009; 53: 1013–1020.

11.

Schreiber

Old

Smyth

. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565–1570.

12.

Kanoh

Rubin

. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590–615.

13.

Kalghatgi

Spina

Costello

. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Sci Transl Med 2013; 5: 192ra85.

14.

Mikawa

Akamatsu

Nishina

. Propofol inhibits human neutrophil functions. Anesth Analg 1998; 87: 695–700.

15.

Clarke

Purdie

Harrison

. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849–852.

16.

Dellinger

Levy

Rhodes

. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165–228.

17.

Cain

Gutierrez del Arroyo

Ackland

. Uncontrolled sepsis: a systematic review of translational immunology studies in intensive care medicine. Intensive Care Med Experimental 2013; 2: 1–25.

18.

Chang

Hsieh

Liu

. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLos One 2013; 8: e62323.

19.

Vince

. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 2011; 166: 1–15.

20.

Vandenesch

Lina

Henry

. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors? Front Cell Infect Microbiol 2012; 2: 12.

21.

Adib-Conquy

Cavaillon

J-M

. Compensated anti-inflammatory response syndrome. Thromb Haemost 2009; 101: 36–47.

22.

Seok

Warren

Cuenca

. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507–3512.

23.

Xiao

Mindrinos

Seok

. A genomic storm in critically injured humans. J Exp Med 2011; 208: 2581–2590.

24.

De Maio

Torres

Reeves

. Genetic determinants influencing the response to injury, inflammation, and sepsis. Shock 2005; 23: 11–17.

25.

Stewart

Fulton

Wilson

. Genetic contribution to the septic response in a mouse model. Shock 2002; 18: 342–347.

26.

Radermacher

Haouzi

. A mouse is not a rat is not a man: species-specific metabolic responses to sepsis – a nail in the coffin of murine models for critical care research? Intensive Care Med Experimental 2013; 1: 7.

27.

Doevendans

Daemen

de Muinck

. Cardiovascular phenotyping in mice. Cardiovasc Res 1998; 39: 34–49.

28.

Salzman

de Jong

Paterson

. Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology 2002; 148: 3651–3660.

29.

Rehli

. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002; 23: 375–378.

30.

Lund

Sato

Akira

. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513–520.

31.

Risso

. Leukocyte antimicrobial peptides: multifunctional effect or molecules of innate immunity. J Leukoc Biol 2000; 68: 785–792.

32.

Warren

. Editorial: mouse models to study sepsis syndrome in humans. J Leukoc Biol 2009; 86: 199–201.

33.

Doeing

Borowicz

Crockett

. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol 2003; 3: 3.

34.

Macchiarini

Manz

Palucka

. Humanized mice: are we there yet? J Exp Med 2005; 202: 1307–1311.

35.

Shultz

Ishikawa

Greiner

. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118–130.

36.

Martin

Mannino

Eaton

. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546–1554.

37.

Singer

De Santis

Vitale

. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364: 545–548.

38.

Singer

Glynne

. Treating critical illness: the importance of first doing no harm. PLoS Med 2005; 2: e167.

39.

Andreasen

Krabbe

Krogh-Madsen

. Human endotoxemia as a model of systemic inflammation. Curr Med Chem 2008; 15: 1697–1705.

40.

Krabbe

Bruunsgaard

Hansen

. Ageing is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol 2001; 8: 333–338.

41.

Damas

Ledoux

Nys

. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356–362.

42.

Futier

Constantin

Paugam-Burtz

. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med 2013; 369: 428–437.

43.

Brower

Fessler

. Mechanical ventilation in acute lung injury and acute respiratory distress syndrome. Clin Chest Med 2000; 21: 491–510, viii.

44.

Wang

Shapiro

Griffin

. Chronic medical conditions and risk of sepsis. PLoS One 2012; 7: e48307.

45.

Weiser

Regenbogen

Thompson

. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008; 372: 139–144.

46.

Pearse

Harrison

James

. Identification and characterisation of the high-risk surgical population in the United Kingdom. Crit Care 2006; 10: R81.

47.

Greif

Akca

Horn

. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med 2000; 342: 161–167.

48.

Belda

Aguilera

Garcia de la Asuncion

. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. JAMA 2005; 294: 2035–2042.

49.

Melling

Ali

Scott

. Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. Lancet 2001; 358: 876–880.

50.

Charlson

Szatrowski

Peterson

. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.

51.

Warnold

Lundholm

. Clinical significance of preoperative nutritional status in 215 noncancer patients. Ann Surg 1984; 199: 299–305.

52.

Windsor

Hill

. Weight loss with physiologic impairment. A basic indicator of surgical risk. Ann Surg 1988; 207: 290–296.

53.

Copeland

Jones

Walters

. POSSUM: a scoring system for surgical audit. Br J Surg 1991; 78: 355–360.

54.

Manilich

Vogel

Kiran

. Key factors associated with postoperative complications in patients undergoing colorectal surgery. Dis Colon Rectum 2013; 56: 64–71.

55.

Gupta

Schuller

. Development and validation of a risk calculator for predicting postoperative pneumonia. Mayo Clinic Proc 2013; 88: 1241–1249.

56.

Bateman

Schmidt

Berman

. Temporal trends in the epidemiology of severe postoperative sepsis after elective surgery: a large, nationwide sample. Anesthesiology 2010; 112: 917–925.

57.

Lee

Marcantonio

Mangione

. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043–1049.

58.

Angus

Linde-Zwirble

Lidicker

. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–1310.

59.

Morris

. Treatment algorithms and protocolized care. Curr Opin Crit Care 2003; 9: 236–240.

60.

Stringer

. Cardiopulmonary exercise testing: current applications. Expert Rev Resp Med 2010; 4: 179–188.

61.

White

Mahon

Grealy

. Post-operative infection and sepsis in humans is associated with deficient gene expression of gammac cytokines and their apoptosis mediators. Crit Care 2011; 15: R158.

62.

Henriksen

Hessov

Dela

. Effects of preoperative oral carbohydrates and peptides on postoperative endocrine response, mobilization, nutrition and muscle function in abdominal surgery. Acta Anaesthesiol Scand 2003; 47: 191–199.

63.

Kobayashi

Mohri

Inoue

. Continuous follow-up of surgical site infections for 30 days after colorectal surgery. World J Surg 2008; 32: 1142–1146.

64.

Brealey

Brand

Hargreaves

. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360: 219–223.

65.

Moore

Poggetti

. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma 1991; 31: 629–636.

66.

Izquierdo

Ruiz-Granell

Bonanad

. Value of early cardiovascular magnetic resonance for the prediction of adverse arrhythmic cardiac events after a first noncomplicated ST-segment-elevation myocardial infarction. Circ Cardiovasc Imaging 2013; 6: 755–761.

67.

Purdon

Pierce

Bonmassar

. Simultaneous electroencephalography and functional magnetic resonance imaging of general anesthesia. Ann New York Acad Sci 2009; 1157: 61–70.

68.

Zhang

Raoof

Chen

. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104–107.

69.

Simmons

Lee

Mulekar

. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. Ann Surg 2013; 258: 591–596.

70.

Bianchetti

Lucchini

Crosti

. Dependence of mitochondrial protein synthesis initiation on formylation of the initiator methionyl-tRNAf. J Biol Chem 1977; 252: 2519–2523.

71.

Taanman

. The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta 1999; 1410: 103–123.

72.

Wrigge

Zinserling

Stuber

. Effects of mechanical ventilation on release of cytokines into systemic circulation in patients with normal pulmonary function. Anesthesiology 2000; 93: 1413–1417.

73.

Perkins

Gates

Park

. The beta agonist lung injury trial prevention. A randomized controlled trial. Am J Respir Crit Care Med 2014; 189: 674–683.

74.

Shyamsundar

McAuley

Shields

. Effect of simvastatin on physiological and biological outcomes in patients undergoing esophagectomy: a randomized placebo-controlled trial. Ann Surg 2014; 259: 26–31.

75.

McAuley

Laffey

O'Kane

. Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014; 371: 1695–1703.

76.

Koike

Moore

. Endotoxin after gut ischemia/reperfusion causes irreversible lung injury. J Surg Res 1992; 52: 656–662.

77.

Condliffe

Kitchen

Chilvers

. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci 1998; 94: 461–471.

78.

Moore

Harken

. The two-event construct of postinjury multiple organ failure. Shock 2005; 24 Suppl 1: 71–74.

79.

Barsness

Arcaroli

Harken

. Hemorrhage-induced acute lung injury is TLR-4 dependent. Am J Physiol Regul Integr Comp Physiol 2004; 287: R592–R599.

80.

Ayala

Chung

Lomas

. Shock-induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency. Am J Pathol 2002; 161: 2283–2294.

81.

Xiang

Shi

. Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. J Immunol 2011; 187: 4809–4817.

82.

Buttenschoen

Schneider

Utz

. Effect of major abdominal surgery on endotoxin release and expression of Toll-like receptors 2/4. Langenbecks Arch Surg 2009; 394: 293–302.

83.

Limaye

Kirby

Rubenfeld

. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008; 300: 413–422.

84.

Luyt

Combes

Deback

. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175: 935–942.

85.

Guan

Liu

Lin

. Severe sepsis facilitates intestinal colonization by ESBL-producing klebsiella pneumoniae and transfer of the SHV-18 resistance gene to escherichia coli during antimicrobial treatment. Antimicrob Agents Chemother 2014; 58: 1039–1046.

86.

Hotchkiss

Tinsley

Swanson

. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166: 6952–6963.

87.

Ni Choileain

MacConmara

Zang

. Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol 2006; 176: 225–236.

88.

Delano

Scumpia

Weinstein

. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463–1474.

89.

Bhatti

Peacock

Lloyd

. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197–203.

90.

Garcea

Ladwa

Neal

. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surgery 2011; 35: 868–872.

91.

Bhutta

Agha

Wong

. Neutrophil-lymphocyte ratio predicts medium-term survival following elective major vascular surgery: a cross-sectional study. Vasc Endovasc Surg 2011; 45: 227–231.

92.

Gibson

Croal

Cuthbertson

. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J 2007; 154: 995–1002.

93.

MacLean

Meakins

Taguchi

. Host resistance in sepsis and trauma. Ann Surg 1975; 182: 207–217.

94.

Savage

. Microbial ecology of the gastrointestinal tract. Ann Rev Microbiol 1977; 31: 107–133.

95.

Morowitz

Babrowski

Carlisle

. The human microbiome and surgical disease. Ann Surg 2011; 253: 1094–1101.

96.

Ackland

Grocott

Mythen

. Understanding gastrointestinal perfusion in critical care: so near, and yet so far. Crit Care 2000; 4: 269–281.

97.

Alverdy

Holbrook

Rocha

. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: evidence for in vivo virulence expression in Pseudomonas aeruginosa. Ann Surg 2000; 232: 480–489.

98.

Marshall

Foster

Vincent

. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004; 190: 527–534.

99.

Roumen

Frieling

van Tits

. Endotoxemia after major vascular operations. J Vasc Surg 1993; 18: 853–857.

100.

Rothenburger

Soeparwata

Deng

. The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. J Am Coll Cardiol 2001; 38: 124–130.

101.

Bennett-Guerrero

Panah

Barclay

. Decreased endotoxin immunity is associated with greater mortality and/or prolonged hospitalization after surgery. Anesthesiology 2001; 94: 992–998.

102.

Cruz

Antonelli

Fumagalli

. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301: 2445–2452.

103.

Raghunathan

Shaw

Nathanson

. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med 2014; 42: 1585–1591.

104.

Pro CESS Investigators, Yealy

Kellum

. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370: 1683–1693.

105.

Bone

Balk

Cerra

. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest 1992; 101: 1644–1655.

106.

Caironi

Tognoni

Masson

. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370: 1412–1421.

107.

Asfar

Meziani

Hamel

. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014; 370: 1583–1593.

108.

Gordon

Mason

Perkins

. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 2014; 42: 1325–1333.

109.

Bernard

Francois

Mira

. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-alpha fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med 2014; 42: 504–511.

110.

Morelli

Ertmer

Westphal

. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013; 310: 1683–1691.

111.

Mollen

Anand

Tsung

. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26: 430–437.